National Survey of Pre- and Post- Analytical Performance Measures Used in Newborn Screening Programs



Similar documents
Texas Newborn Screening Performance Measures Project

HEALTH RESEARCH, INC. New York State Department of Health Wadsworth Center/Division of Genetics

Maryland State Sickle Cell Disease Follow Up Program SCDAA 41 st Annual Convention September 27, 2013

Overview of Hospital Utilization Review

LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION

Sutter Health Support Services Shared Laboratory Position Description. Incumbent: Laboratory Date: October 23, 2006 Written By: Michele Leonard

Patient name; Patient address; Patient Social Security number/medical Record number; Patient date of birth; Patient phone number; Diagnosis code(s);

Newborn Screening Issues

Chapter 6 Case Ascertainment Methods

HIPAA Notice of Privacy Practices

Laboratory Director Responsibilities

Health and Human Services Commission Department of State Health Services

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:

A LEAN SIX SIGMA APPROACH TO CONTINUOUS QUALITY IMPROVEMENT IN THE TEXAS NEWBORN SCREENING PROGRAM

Health Information Technology Survey for Newborn Screening Programs SUMMARY DATA REPORT

New Estimates of the Economic Benefits of Newborn Screening for Congenital Hypothyroidism in the US

Wellness Consultation Policies. HIPAA Notice of Privacy Practices

REGISTRATION FORM. How would you like to receive health information? Electronic Paper In Person. Daytime Phone Preferred.

Individualized Quality Control Plan

Policy and Procedure Manual

Newborn Screening Test

LAP Audioconference How to Prepare and Comply with Your Quality Management Plan* February 18, 2009

Examples: collecting the right sample on the right patient; labeling the sample accurately;

GENETIC COUNSELING IS IT A CAREER FOR YOU? Judith L Miller, MS, LGC April 8, 2014

HIPAA-ACKNOWLEDGEMENT OF RECEIPT Notice of Privacy Practices

Maggie Dreon, MS, CGC Jessica Tarnowski

This program is cosponsored by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL).

Contact Information: West Texas Health Information Technology Regional Extension Center th Street MS 6232 Lubbock, Texas

The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011

ADA-Sponsored Disability Income Protection Plan Application for Insurance

Medical Laboratory Technician AAS Program

504 Lavaca Street Suite 850 Austin, Texas PROVIDER NEWSLETTER

Clinical Decision Making: Promoting Appropriate Reporting and Understanding of Molecular Genetic Test Results

Be your Own Consultant Checklist for Practice Manager

Home Office Use Only. Section B TYPE OF CLAIM: FIRST CLAIM CONTINUED CLAIM

2010 Laboratory Accreditation Program Audioconference. Accreditation Requirements for Waived Vs. Non-waived Tests


CLINICAL COURSE PROGRESSION AND CLINICAL REQUIREMENTS FOR FAMILY NURSE PRACTITIONER (FNP) STUDENTS

Medical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives

Using and Maintaining Documents and Records. Finding the information when you need it

SMANN News! Volume 24 Issue 1

Graduate Student Epidemiology Program

Public Health Reporting Initiative Functional Requirements Description

2009 LAP Audioconference Series. How to Prepare and Comply with Your Quality Management Plan

A Guideline for California From California Public Protection and Physician Health, Inc.

Patient Safety and the Laboratory

NewSTEPs Collaborative Improvement and Innovation Network (CoIIN) for Timeliness in Newborn Screening January March 2016 Application Form

Improving Treatment for Children with Developmental Disabilities and Birth Defects

DATE APPROVED: DATE EFFECTIVE: Date of Approval. REFERENCE NO. MOH/04 PAGE: 1 of 7

Newborn screening sample collection guidelines

PROPOSAL. Proposal Name: Open Source software for improving Mother and Child Health Services in Pakistan". WHO- Pakistan, Health Information Cell.

Appendix 6.2 Data Source Described in Detail Hospital Data Sets

POLICYHOLDER. Policy No.(s): Waiver of Premium (include life policies) Routine Pregnancy

TOTAL PROCESS MANAGEMENT FOR YOUR NEWBORN SCREENING LABORATORY. Specimen Gate software

DACHDNC Follow-Up and Treatment Subcommittee September 20, Carol Greene, MD, Chair Christopher A. Kus, MD, MPH, Co-Chair

Drug Testing to Support Pain Management

LAKE COUNTY SCHOOLS RECEIPT OF DRUG-FREE WORKPLACE POLICY

Thank you for making a reproductive genetic counseling appointment at the Mount Sinai Medical Center.

ACCOUNTABLE CARE ANALYTICS: DEVELOPING A TRUSTED 360 DEGREE VIEW OF THE PATIENT

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.

Advancing Health Equity. Through national health care quality standards

Canadian Provincial and Territorial Early Hearing Detection and Intervention. (EHDI) Programs: PROGRESS REPORT

Admission to the Second Degree BSCLS Program. Prerequisite Course Requirements for Second Degree BSCLS

CDC CLIA-Related Initiatives to Improve Laboratory Practice A Key Component of Quality Health Care

children who are in a system of care for hearing loss as early as possible, the Mississippi

Testimony of the American College of Nurse-Midwives. at a Hearing of the House Committee on Energy and Commerce Subcommittee on Health.

Unique Standards and Documentation Required for Accredited CLT/MLT Programs

RUBRIC ASSESSMENT: CERTIFIED SCHOOL NURSE (CSN) Date Self-Assessment Evaluator Assessment. Domain 1: Planning and Preparation

RIDGE PHYSICAL THERAPY & WELLNESS CENTER. Intake Form

Transcription:

National Survey of Pre- and Post- Analytical Performance Measures Used in Newborn Screening Programs Simran Tiwana, MBA* Susan Tanksley, PhD* Brad Therrell, PhD Donna Williams, BS* Mirsa Douglass, MBA* Colleen Buechner, MS *= Texas Department of State Health Services = National Newborn Screening and Genetic Resource Center

Introduction Performance Measures: Objective way to measure the degree of success of a program in terms of its goals and objectives Number of clients served Change in attitude Change in knowledge etc. Performance Measures in Newborn Screening: Unsatisfactory rate Number of serious complications avoided Number of deaths avoided etc.

The Texas Newborn Screening Performance Measures Project Three year grant funded by the Centers for Disease Control (CDC) Primary objective to develop evidence-based pre- and post-analytical performance measures to improve the newborn screening system Inputs sought via this survey to help in development of performance measures

Survey Objectives To gather information on: Existing pre-analytical performance measures Existing post-analytical performance measures Agencies/organizations to whom performance measures are reported Frequency of reporting to external agencies/organizations Suggestions for future performance measures to improve the NBS system

Methods Web-based survey sent to all 50 States and District of Columbia Follow-up via telephone

Survey Questions Survey questions allowed structured as well as unstructured (qualitative) responses Example: Within your newborn screening program, which preanalytical performance measures are routinely recorded? The following list includes some common examples please be sure to list any additional measures related to pre-analytical phases of newborn screening. (Choose all options that apply) 1. Number of specimens classified as unsatisfactory because of poor specimen quality 2. Number of specimens classified as unsatisfactory because of insufficient or inaccurate data 3. Time from collection to receipt in the laboratory 4. Other (Please Specify)

Survey Responses States that Responded Alaska and Hawaii responded as well!

Results Number of surveys sent out = 51 Number completed = 35 Response rate = 68.62% Average time taken to complete survey = 11 minutes

Pre-analytical Performance Measures Recorded by State Laboratories (total 103 responses from 35 states) Not applicable = 0 Others = 10 Unsat due to poor specimen quality = 35 Time from collection to receipt in lab = 32 Unsat due to insufficient data = 26

Other Pre-analytical Measures Collected by States Measures related to time Time from birth until specimen collection Time from collection until receipt in the lab Turn-around time within the lab Time from birth until newborn screen result Measures related to errors in data Errors in demographic data entry Specimens drawn before 24 hours or after 7 days Measures related to missing data Missed screens Refused screens

Post-analytical Performance Measures Recorded by State Laboratories (88 responses from 35 states) Time from Not applicable = 1 Time from abnormal screen result until treatment initiation = 25 Others = 14 abnormal screen result until physician contact = 24 Time from abnormal screen result until physician confirms diagnosis = 24

Other Post-analytical Measures Collected by States Time-related Date of physician visit Date of first repeat screen Birth-defects registration date Date of treatment initiation Data on abnormal results Percent abnormal results followed Annual list of confirmed cases detected via screening

Reporting of Performance Measures (58 responses from 35 states) Not Applicable = 1 External stakeholders = 29 Internal reviewers/ executives = 28

Reporting of Performance Measures: Types of External Agencies (97 responses from 35 states) Others = 11 Not applicable = 3 National Database = 21 State Legislature = 6 Contracting agency =10 Advisory committee = 21 Healthcare provider/ birthing facility = 25

Other External Stakeholders Notified by State Programs Medical sub-specialists State Board of Health Newborn screening workgroups Annual report for distribution and on the newborn screening program website

Frequency of Reporting to External Agencies (56 responses from 35 states) Others = 8 Monthly = 15 Not applicable = 3 Annually =12 Quarterly =14 Bi-annually = 4

Performance Measures Suggested for Future Time-related Time from abnormal screen result to physician notification Time from receipt in lab until final result is obtained Transit time Specimen collection time Time from birth until receipt of screening report by medical home

Performance Measures Suggested for Future Disorder-specific Measures Number (%) of infants diagnosed with Sickle Cell Disease and treated before 2 months of age Number (%) of infants diagnosed with PKU and treated before 7 days of age Number (%) of patients with PKU where Phenylalanine levels were maintained in an acceptable range >80% of the time Specimen collected too soon for testing based on condition (e.g. PKU, MSUD, CH, CAH etc.)

Performance Measures Suggested for Future Measures related to specimen quality Unsatisfactory specimen rates Specimen card field completion rate Inadequate specimen rate Hospitals to be informed about number of unsatisfactory specimens etc.

Performance Measures Suggested for Future Measures related to demographic information/birth records Number (%) of births matched with screening records Number (%) of births with documented screening completed Demographic data errors

Performance Measures Suggested for Future Measures related to feedback Long-term follow-up for patient outcomes False negative rate False positive rate False positive rate with second tier testing Periodic distribution of educational materials to families Number (%) of diagnosed cases reported to national system as they are received (without waiting until a specific time) Number (%) lost to follow-up Number (%) no diagnosis for greater than one year

Conclusions Pre- and post-analytical measures collected by all states Disparity in: Types of measures collected Reporting agency Frequency of reporting Not many measures currently being collected on longterm outcomes Measures suggested for the future by some states are already being collected by other states Some suggestions for improvement could apply to all states Need for standardization and uniformity Suggested measures match with suggestions made by the TNSPMP stakeholders, validate those suggestions

Questions?